Search results
Results From The WOW.Com Content Network
Image source: The Motley Fool. Opko Health (NASDAQ: OPK) Q3 2024 Earnings Call Nov 07, 2024, 4:30 p.m. ET. Contents: Prepared Remarks. Questions and Answers. Call ...
OPKO Health (OPK) third-quarter results benefit from higher Product revenues and RAYALDEE prescription growth.
(Reuters) -The U.S. Food and Drug Administration has approved Pfizer Inc and partner OPKO Health Inc's treatment for growth hormone deficiency in children, the companies said on Wednesday. The ...
For premium support please call: 800-290-4726 more ways to reach us
A look at the shareholders of OPKO Health, Inc. can tell us which group is most powerful.The group holding the most number of shares in the company, around 46% to be precise, is individual insiders.
OPKO Health is a diversified healthcare company present in more than 30 countries. The company's primary businesses include [citation needed] Bioreference Laboratories, a clinical laboratory with a core genetic testing business; The 4K Test Score, a blood test for prostate cancer; Pharmaceutical development, with products such as Rayaldee
OPKO Health (OPK) delivered earnings and revenue surprises of -100% and 3.02%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Opko Health announced the initiation of a Phase 2 trial of Rayaldee as a treatment for mild-to-moderate COVID-19. After rising in the pre-market trading hours, Opko stock was down 0.63% at the ...